ICON plc , a global provider of drug and development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the release of the book "Re-Engineering Clinical Trials" , edited and co-authored by Brendan Buckley, ICON's Chief Medical Officer, and Peter SchA1 4ler, ICON's SVP of Global Medical and Safety Services. Joined by co-authors at AstraZeneca, Bayer, Boehringer Ingelheim, IBM, McGill University, the Tufts Center for the Study of Drug Design, and 22 other institutes and companies, Buckley and SchA1 4ler set forth a comprehensive collection of reforms for a progressive model of drug development.